Diffuse Liver Metastases with Minimal Hepatic Dysfunction
- 1University of California, Los Angeles
- 2Department of Medicine University of California, Los Angeles
Abstract
A 47-year-old woman with stage IV breast cancer and liver metastases presented with abdominal pain. Contrast-enhanced computed tomography (CT) of the abdomen and pelvis demonstrated marked hepatomegaly with metastatic lesions replacing most of the hepatic parenchyma. Laboratory evaluations demonstrated only modest elevation of her liver function tests with mildly elevated alkaline phosphatase. She also had preserved hepatic synthetic function. We suggest this was due to several factors. The liver’s substantial functional reserve and regenerative capacity even with up to 80% parenchymal replacement. Tumor metastases forming expansive nodules that displace rather than eradicate hepatocytes. Compensatory hypertrophy of non-malignant hepatic parenchyma with increased metabolic activity, and active hepatic compensation for space-occupying disease known as the “hepatostat” effect. These mechanisms combined to maintain liver function even in an advanced metastatic state. We further suggest that her Alkaline phosphatase elevation was multifactorial due to bone metastases, systemic inflammation and prolonged immobility. Additionally, her younger age, lack of alcohol use, stable nutritional status and other comorbidity also protected her from more severe liver dysfunction.
Related
- Very low-calorie diet reduces hepatic steatosis and remodels circulating metabolite-microRNAs networks in metabolic dysfunction-associated steatotic liver disease: A pilot study
- Comparison of Metabolic Dysfunction‐Associated Steatotic Liver Disease Between Individuals With Werner Syndrome and Those With Insulin‐Resistant Type 2 Diabetes: Hepatic Steatosis and Fibrosis Indices
- Adipose tissue dysfunction and the liver: reframing MASH as the hepatic expression of systemic metabolic dysfunction
- Successive and Isoform-Specific Remodeling of Hepatic Drug-Metabolizing Enzymes during Metabolic Dysfunction-Associated Steatotic Liver Disease/Metabolic Dysfunction-Associated Steatohepatitis Progression
- Circulating Tumor DNA in Resected Colorectal Liver Metastases: From Minimal Residual Disease Detection to Treatment Guidance—A Systematic Review
BibTeX
@article{moon2026diffuse,
title = {{Diffuse Liver Metastases with Minimal Hepatic Dysfunction}},
author = {Rony Moon and Elaine J Chiao and Zoee U. D’Costa and Michael E Lazarus},
journal = {Journal of Brown hospital medicine},
year = {2026},
month = oct,
doi = {10.56305/001c.168504},
url = {https://europepmc.org/article/PMC/PMC13730613},
note = {CC BY-NC},
}
RIS
TY - JOUR
TI - Diffuse Liver Metastases with Minimal Hepatic Dysfunction
AU - Rony Moon
AU - Elaine J Chiao
AU - Zoee U. D’Costa
AU - Michael E Lazarus
PY - 2026
DA - 2026/10/01
JO - Journal of Brown hospital medicine
DO - 10.56305/001c.168504
UR - https://europepmc.org/article/PMC/PMC13730613
AB - A 47-year-old woman with stage IV breast cancer and liver metastases presented with abdominal pain. Contrast-enhanced computed tomography (CT) of the abdomen and pelvis demonstrated marked hepatomegaly with metastatic lesions replacing most of the hepatic parenchyma. Laboratory evaluations demonstrated only modest elevation of her liver function tests with mildly elevated alkaline phosphatase. She also had preserved hepatic synthetic function. We suggest this was due to several factors. The liver’s substantial functional reserve and regenerative capacity even with up to 80% parenchymal replacement. Tumor metastases forming expansive nodules that displace rather than eradicate hepatocytes. Compensatory hypertrophy of non-malignant hepatic parenchyma with increased metabolic activity, and active hepatic compensation for space-occupying disease known as the “hepatostat” effect. These mechanisms combined to maintain liver function even in an advanced metastatic state. We further suggest that her Alkaline phosphatase elevation was multifactorial due to bone metastases, systemic inflammation and prolonged immobility. Additionally, her younger age, lack of alcohol use, stable nutritional status and other comorbidity also protected her from more severe liver dysfunction.
SN - 2994-5593
ER -